Drug Database
Back to search

Poland· PL-100505930

Kayfanda

A odevixibat product containing odevixibatum, registered in Poland by Ipsen Pharma. The same ATC class is registered in 15 of our 19 countries.

ATC A05AX05

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedKayfandaATCA05AX05REGISTER NO.PL-100505930PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about odevixibatumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Odevixibat is registered in 15 of 19 countries.

Countries holding a registration under ATC A05AX05 (odevixibat), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose
Search odevixibat products by name

Odevixibat · ATC A05AX05

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Odevixibatum
Manufacturer
Ipsen Pharma
Country
Poland (PL)
ATC code
A05AX05
ATC class
Odevixibat
Defined daily dose
2.4 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    03582180003295

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Odevixibat in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All odevixibat products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Bylvay, Kayfanda
  • Liechtenstein · Bylvay, Kayfanda
  • Norway · Bylvay, Kayfanda

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/cfff9f58-78e2-4117-a085-0e37c0140e86
GET /v1/drugs/cfff9f58-78e2-4117-a085-0e37c0140e86?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Kapsułki twarde",
  "source": "urpl",
  "strength": "400 mcg",
  "packaging": "03582180003295 ¦ Rpz ¦ EU/1/24/1854/002 ¦ 158209\n30 kaps.\n¦ UR/Z/4c/098/25 - 03582180003295",
  "substance": "Odevixibatum 400 mcg",
  "common_name": "Odevixibatum",
  "pl_product_id": "100505930",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about odevixibat.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console